“As progression-free survival (PFS)


“As progression-free survival (PFS) learn more has become increasingly used as the primary endpoint

in oncology phase III trials, the U.S. Food and Drug Administration (FDA) has generally required a complete-case blinded independent central review (BICR) of PFS to assess and reduce potential bias in the investigator or local site evaluation. However, recent publications and FDA analyses have shown a high correlation between local site evaluation and BICR assessments of the PFS treatment effect, which questions whether complete-case BICR is necessary. One potential alternative is to use BICR as an audit tool to detect evaluation bias in the local site evaluation. In this article, the performance characteristics of two audit methods proposed in the literature are evaluated on 26 prospective, randomized phase III registration trials

in nonhematologic malignancies. The results support HSP990 concentration that a BICR audit to assess potential bias in the local site evaluation is a feasible approach. However, implementation and logistical challenges need further consideration and discussion. (C) 2013 AACR.”
“Objective: Several genome-wide association studies and replication analyses have identified common variation at the insulin-like binding protein 2 (IGF2BP2) gene to be associated with type 2 diabetes (T2DM). The aim of this study was to replicate in a Lebanese Arab population identified associations of IGF2BP2 variants rs4402960 and rs1470579 with T2DM.\n\nMethods: This case-control study involved 544 T2DM patients and 606 control subjects. Genotyping was done by the allelic exclusion method.\n\nResults: T allele of rs440960 (P = 6.5 x 10(-6)) and C allele of rs1470579 (P = 5.3 x 10(-4)) were significantly associated with T2DM; both SNPs were in strong LD (D’ = 0.83, r(2) = 0.58). While both IGF2BP2 SNPs were significantly associated with T2DM under additive and recessive models, only rs4402960 remained significantly associated with T2DM under the dominant model. Taking

the common rs4402960/rs1470579 GA haplotype as reference, Selleck SBC-115076 multivariate analysis confirmed the positive association of TC (P = 0.009; OR, 1.43; 95% CI, 1.09-1.87), and TA (P < 0.001; OR = 5.49; 95% CI = 2.09-14.39) haplotypes with increased T2DM risk. These differences remained significant after applying the Bonferroni correction for multiple testing.\n\nConclusion: We validate that IGF2BP2 susceptibility variants rs4402960 and rs1470579 associate with T2DM in Lebanese Arabs. (C) 2012 Elsevier Ireland Ltd. All rights reserved.”
“An ensemble-based approach is applied to better estimate source impacts on fine particulate matter (PM2.5) and quantify uncertainties in various source apportionment (SA) methods. The approach combines source impacts from applications of four individual SA methods: three receptor-based models and one chemical transport model (CTM).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>